By Martin Burns
Contact lens manufacturer Bausch + Lomb (B+L) has announced it is to acquire the product Miochol(R)-E in a deal which affects the US, Canadian, Australian and Korean markets.
Miochol(R)-E is an injectable miotic pharmaceutical used during eye surgery to constrict the pupil and it is currently owned by affiliates of Novartis AG, though Bausch + Lomb revealed that it is close to completing the acquisition of the remaining assets and intellectual property.
In the global market there are currently only two injectable miotics products available, of which Miochol(R)-E is one, and Brent Saunders, chief executive of B+L, said the acquisition adds "further diversity" to its ophthalmic pharmaceuticals portfolio.
Dr David Ritterband, clinical associate professor of ophthalmology at the New York Eye and Ear Infirmary and New York Medical College, added: "Miochol(R)-E has been widely used by ophthalmic surgeons for nearly 20 years. Adding this trusted product to Bausch + Lomb's quality eye health product line is a perfect fit for B+L and its patients."
Recently, the contact lens manufacturer announced the appointment of Rodney Unsworth as the new president for its Asia-Pacific division.
by Martin Burns